Intelligence · Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring ≤24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.
-
US 9447406
Chemically modified cystathionine beta-synthase enzyme for treatment of homocystinuria
granted -
US 9446075
Compositions derived from stem cell released molecules and methods for formulation thereof
granted -
US 9446022
Pro-neurogenic compounds
granted -
US 9447405
Regulation of specific spinal neurons regulating pain transmission via chimeric toxins
granted -
US 9447390
Aldehyde tags, uses thereof in site-specific protein modification
granted -
US 9447155
Isoform Nell-1 peptide
granted -
US 9447047
Inhibitors of protein phosphatase-1 and uses thereof
granted -
US 9446125
Anti-EphA2 antibodies and methods of use thereof
granted -
US 9446107
Scaffolds for cell transplantation
granted -
US 9446067
Mercapto-modified biocompatible macromolecule derivatives with low degree of mercapto-modification and the cross-linked materials and uses thereof
granted -
US 9446042
Pro-neurogenic compounds
granted -
US 9446010
Compounds and methods for treating aberrant adrenocortical cell disorders
granted -
US 9439889
Methods employing wolbachia FtsZ as a target for albendazole sulfone
granted -
US 9441202
Molecules with effects on cellular development and function
granted -
US 9441014
Skin permeating and cell entering (SPACE) peptides and methods of use thereof
granted -
US 9441013
Melanocortin 1 receptor ligands and methods of use
granted -
US 9439984
Macrocycles
granted -
US 9439976
Compositions and methods for using cathepsin E cleavable substrates
granted -
US 9439948
Degradable cage coated with mineral layers for spinal interbody fusion
granted -
US 9439928
Method for combined conditioning and chemoselection in a single cycle
granted -
US 9439958
Stabilized virus like particles having enhanced mucosal immunogenicity
granted -
US 9441244
Mutant adeno-associated virus virions and methods of use thereof
granted -
US 9440967
1H-pyrrolo [2, 3 -B] pyridine derivatives and their use as radical quenchers
granted -
US 9433686
Methods for treating castration resistant prostate cancer and metastasis by reducing B-cell number and/or function
granted -
US 9435804
Detection, prevention, and treatment of anthrax and other infectious diseases
granted -
US 9428731
Technologies, methods, and products of small molecule directed tissue and organ regeneration from human pluripotent stem cells
granted -
US 9428561
Polypeptide-polymer conjugates and methods of use thereof
granted -
US 9427472
Controlled release compositions for modulating free-radical induced damage and methods of use thereof
granted -
US 9427469
Soluble physiological chitosan formulations combined with platelet-rich plasma (PRP) for tissue repair
granted -
US 9427410
Formulation of acoustically activatable particles having low vaporization energy and methods for using same
granted -
US 9428749
Control of whole body energy homeostasis by microRNA regulation
granted -
US 9422340
Macrocyclic compounds useful as inhibitors of histone deacetylases
granted -
US 9421185
Diagnosis and treatment methods for entry of gastrointestinal contents into respiratory tract
granted -
US 9421241
Therapeutic modulation of ocular surface lubrication
granted -
US 9422318
Epoxyeicosatrienoic acid analogs and methods of making and using the same
granted -
US 9422522
Method of producing adipocytes from fibroblast cells
granted -
US 9422347
Algal produced malarial transmission blocking vaccines
granted -
US 9422529
Alphavirus compositions and methods of use
granted -
US 9422352
PTD-SMAD7 therapeutics
granted -
US 9415110
Method and compositions for targeted drug delivery to the lower GI tract
granted -
US 9415123
Polymeric nanoparticles for ultrasound imaging and therapy
granted -
US 9416162
Peptides having reduced toxicity that stimulate cholesterol efflux
granted -
US 9415135
Methods and compositions for stabilizing the myocardium
granted -
US 9415006
Immunogenic compositions comprising nanoemulsion and hepatitis B virus immunogen and methods of using the same
granted -
US 9416165
Methods of inhibiting viral replication and improving T cell function employing soluble Tim-3 inhibitors
granted -
US 9409965
Kidney-specific tumor vaccine directed against kidney tumor antigen G-250
granted -
US 9409880
Modulators of TLR3/dsRNA complex and uses thereof
granted -
US 9409963
Fibromodulin peptide
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory